The prevalence of metabolic syndrome and Framingham cardiovascular risk scores in adult inpatients taking antipsychotics - A retrospective medical records review

Psychiatria Danubina

Volumn 24, Issue 3, 2012, Pages 314-322

  Wysokiński, Adam ^a   Kowman, Maciej ^a   Kłoszewska, Iwona ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Antipsychotics; Cardiovascular risk; Metabolic syndrome

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LITHIUM CARBONATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRIACYLGLYCEROL; VALPROIC ACID;

ABDOMINAL OBESITY; ADULT; BLOOD PRESSURE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DYSLIPIDEMIA; FEMALE; FRAMINGHAM CARDIOVASCULAR RISK SCORE; GENDER; GLUCOSE BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PSYCHOSIS; RATING SCALE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SCORING SYSTEM; SMOKING HABIT; WAIST CIRCUMFERENCE;

ADULT; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INPATIENTS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PREVALENCE; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SMOKING;

EID: 84867761435     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Alberti KG, Zimmet P, Shaw J: The metabolic syndrome - a new worldwide definition. Lancet 2005; 366:1059-1062. (Pubitemid 41338752)
2. Alberti KG, Zimmet P, Shaw J: Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23:469-480.
3. Arango C, Bobes J, Aranda P, Carmena R, Garcia-Garcia M, Rejas J: A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. Schizophr Res 2008; 104:1-12.
4. Brown S, Inskip H, Barraclough B: Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177:212-217.
5. Castelli WP, Abbott RD, McNamara PM: Summary estimates of cholesterol used to predict coronary heart disease. Circulation 1983; 67:730-734. (Pubitemid 13161449)
6. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004a; 27:596-601.
7. Correll CU, Frederickson AM, Kane JM, Manu P: Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 2006; 67:575-583. (Pubitemid 43764234)
8. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB: Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke 1994; 25:40-43.
9. D'Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW, Hartz SC: Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000; 139:272-281. (Pubitemid 30090804)
10. D'Agostino RBS, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB: General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117:743-753. (Pubitemid 351640675)
11. De Hert MA, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J: Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006; 83:87-93.
12. Dervaux A, Laqueille X: Smoking and schizophrenia: epidemiological and clinical features. Encephale 2008; 34:299-305.
13. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004b; 27 Suppl 1: S5-S10.
14. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
15. Fontaine KR, Heo M, Harrigan EP, Shear CL, Lakshminarayanan M, Casey DE, Allison DB:Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 2001; 101:277-288. (Pubitemid 32324233)
16. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287:356-359. (Pubitemid 34251969)
17. Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, et al: A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005; 80:45-53. (Pubitemid 41587462)
18. Grundy SM, Brewer HBJ, Cleeman JI, Smith SCJ, Lenfant C: Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109:433-438. (Pubitemid 38133916)
19. Hildrum B, Mykletun A, Hole T, Midthjell K, Dahl AA: Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study. BMC Public Health 2007; 7:220.
20. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K: Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164:1066-1076. (Pubitemid 38668985)
21. Jin H, Folsom D, Sasaki A, Mudaliar S, Henry R, Torres M, et al: Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms. Schizophr Res 2011; 125:295-299.
22. Kozumplik O, Uzun S, Jakovljević M: Metabolic syndrome in patients with psychotic disorders: diagnostic issues, comorbidity and side effects of antipsychotics. Psychiatr Danub 2010; 22:69-74.
23. Krane-Gartiser K, Breum L, Glumrr C, Linneberg A, Madsen M, Koster A, et al: Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics. Nord J Psychiatry 2011; 65:345-352.
24. Maumus S, Marie B, Siest G, Visvikis-Siest S: A prospective study on the prevalence of metabolic syndrome among healthy french families: two cardiovascular risk factors (HDL cholesterol and tumor necrosis factor-alpha) are revealed in the offspring of parents with metabolic syndrome. Diabetes Care 2005; 28:675-682. (Pubitemid 40315331)
25. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80:19-32. (Pubitemid 41587460)
26. McIntyre RS, Park KY, Law CW, Sultan F, Adams A, Lourenco MT, et al: The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. CNS Drugs 2010; 24:741-753.
27. Misawa F, Shimizu K, Fujii Y, Miyata R, Koshiishi F, Kobayashi M, et al: Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study. BMC Psychiatry 2011; 11:118.
28. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M: Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders--A Systematic Review and Meta-Analysis. Schizophr Bull 2011; doi: 10.1093/schbul/sbr148.
29. Parikh NI, Pencina MJ, Wang TJ, Benjamin EJ, Lanier KJ, Levy D, et al: A risk score for predicting near-term incidence of hypertension: the Framingham Heart Study. Ann Intern Med 2008; 148:102-110. (Pubitemid 351651553)
30. Parks J, Svendsen D, Singer P, Foti M: Morbidity and mortality in people with serious mental illness. National Association of State Mental Health Program Directors (NASMHPD) Medical Directors Council, 2006.
31. Schuitemaker GE, Dinant GJ, van der Pol GA, van Wersch JW: Relationship between smoking habits and low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol, and triglycerides in a hypercholesterolemic adult cohort, in relation to gender and age. Clin Exp Med 2002; 2:83-88. (Pubitemid 34969477)
32. Sicras-Mainar A, Blanca-Tamayo M, Rejas-Gutierrez J, Navarro-Artieda R: Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database. Eur Psychiatry 2008; 23:100-108. (Pubitemid 351284507)
33. Sidorenkov O, Nilssen O, Brenn T, Martiushov S, Arkhipovsky VL, Grjibovski AM: Prevalence of the metabolic syndrome and its components in Northwest Russia: the Arkhangelsk study. BMC Public Health 2010; 10:23.
34. Smith SS, Fiore MC: The epidemiology of tobacco use, dependence, and cessation in the United States. Prim Care 1999; 26:433-461. (Pubitemid 29441991)
35. Szurkowska M, Szafraniec K, Gilis-Januszewska A, Pach D, Krzentowska A, Szybinski Z, Huszno B: Prevalence of the metabolic syndrome and its components in adult inhabitants of Krakow. Przegl Lek 2006; 63:733-737.
36. Teixeira PJ, Rocha FL: The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr 2007; 29:330-336. (Pubitemid 351358057)
37. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847. (Pubitemid 28213628)
38. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RBS: Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 2007; 167:1068-1074. (Pubitemid 46835795)
39. Yumru M, Savas HA, Kurt E, Kaya MC, Selek S, Savas E, et al: Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 2007; 98:247-252. (Pubitemid 46151723)